Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Shares Outstanding for 5 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 59.87% year-over-year to $6.2 million, compared with a TTM value of $6.2 million through Dec 2025, up 59.87%, and an annual FY2025 reading of $6.2 million, up 59.87% over the prior year.
  • Shares Outstanding was $6.2 million for Q4 2025 at Aligos Therapeutics, roughly flat from $6.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $43.5 million in Q2 2023 and bottomed at $1.7 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $21.0 million, with a median of $6.2 million recorded in 2025.
  • The sharpest move saw Shares Outstanding plummeted 95.98% in 2022, then soared 92.74% in 2025.
  • Year by year, Shares Outstanding stood at $42.7 million in 2021, then tumbled by 95.98% to $1.7 million in 2022, then soared by 74.96% to $3.0 million in 2023, then rose by 28.65% to $3.9 million in 2024, then soared by 59.87% to $6.2 million in 2025.
  • Business Quant data shows Shares Outstanding for ALGS at $6.2 million in Q4 2025, $6.2 million in Q3 2025, and $6.2 million in Q2 2025.